These findings provided new insights into the mechanisms that control glycolysis and aggressive phenotypes in PC, and highlighted LINC01448, miR-505 and HK2 as potential targets for therapeutic intervention in patients with PC. The gene discussed is HK2; the disease is pachyonychia congenita.